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Introduction
In settings where pneumonia, diarrhea, and malnutrition are major causes of infant mortality, 
breastfeeding for 12 months combined with antiretroviral (ARV) and cotrimoxazole 
preventive therapy (CPT) offers infants of HIV-infected mothers the greatest chance for 
HIV-free survival and is recommended by the World Health Organization [1]. Clinical trials 
showing the efficacy of ARV regimens for reduced risk of HIV transmission to breastfeeding 
infants and those showing the efficacy of CPT against opportunistic infections [2–4] have 
independently shown good overall safety. However, both maternal and infant antiretroviral 
and cotrimoxazole prophylaxis have been independently associated with reports of 
hematologic toxicities, including neutropenia and anemia [5–16]. These conditions, 
particularly severe anemia, are major causes of morbidity in Malawi and sub-Saharan Africa 
[17–20]. Given the similar hematologic side-effects for some antiretroviral agents and 
cotrimoxazole, it is important to evaluate the impact of their concurrent use among HIV-
exposed, uninfected (HEU) infants.
We conducted a secondary analysis of data from the Breastfeeding, Antiretrovirals and 
Nutrition (BAN), a clinical trial of 2,369 mother-infant pairs randomized to 28 weeks of 
infant nevirapine, maternal ARVs, or neither for the prevention of HIV transmission during 
breastfeeding (www.ClinicalTrials.gov number NCT00164736) [21]. During the study, new 
guidelines were issued for the use of CPT in HEU infants. We used data from this 
randomized ARV design and mid-study implementation of CPT to evaluate the independent 
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and concurrent effects of ARV and CPT on the risk of hematologic toxicities, including 
neutropenia, anemia, and elevated alanine transaminase (ALT) among HEU infants.
Methods
Study enrollment, design and procedures
Infants were enrolled in the BAN trial in Lilongwe, Malawi between March 2004 and 
January 2010. The BAN study design and primary findings have been reported elsewhere 
and indicate that the use of either maternal triple ARV prophylaxis or infant nevirapine for 
28 weeks is effective in reducing HIV transmission during breastfeeding [21, 22].
From March 2004 to February 2009, the study screened 3,572 ARV-naive, HIV-infected 
pregnant women attending antenatal clinics in Lilongwe, Malawi, and enrolled 2,369 women 
who met antenatal and postnatal eligibility criteria. The antenatal criteria were age ≥ 14 
years, no serious complications of pregnancy, no prior ARV use, CD4+ count ≥250 cells/µL 
(≥200 cells/µL before July 24, 2006), hemoglobin ≥ 7g/dL, plasma alanine aminotransferase 
(ALT) ≤2.5 times the upper limit of normal, and planning to breastfeed. The postnatal 
criteria were infant birth weight ≥2,000 g, no infant or maternal condition precluding study 
interventions, and the mother’s acceptance of the perinatal antiretroviral regimen and 
treatment assignment within 36 hours of delivery.
All mothers in labor and their newborn infants received a single dose of oral nevirapine and 
7 days of zidovudine, 300 mg, plus lamivudine, 150 mg twice-daily from the onset of labor 
for the mothers and zidovudine (2 mg per kilogram of body weight) and lamivudine (4 mg 
per kilogram) twice-daily for the infants. Mother-infant pairs who met eligibility criteria 
were randomly assigned to one of three ARV intervention arms to be initiated at birth and 
continued for 28 weeks or until breastfeeding cessation, if earlier: 1) infant nevirapine, 2) 
maternal triple-drug antiretroviral regimen, or 3) control (no mother or infant treatment). 
Using a standardized protocol derived from the WHO Breastfeeding Counseling Training 
Manual [23], all mothers were individually counseled to breastfeed exclusively for the first 
24 weeks postpartum and then wean rapidly between 24 and 28 weeks. Due to 
overwhelming evidence of the benefit of the treatment arms, the Data Safety and Monitoring 
Board halted enrollment to the control arm after 668 mother-infant pairs had been assigned; 
participants in the control arm at that time were given the option of switching to the infant 
nevirapine or maternal ARV arms for the remainder of the 28-week intervention period.
Mother-infant pairs were followed at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42, and 48 
weeks post-partum, with the last pair completing follow-up in January, 2010. Infants who 
tested HIV positive were disenrolled and referred for care. A full blood count and ALT 
testing was done at birth, 2, 6, 12, 18, 24, 28, 36 and 48 weeks. Data capturing 
anthropometrics, vital signs, illnesses and hospitalizations since the last visit, current 
symptoms, and physical exam findings were collected at all follow-up visits. Participants 
were advised to return to the clinic between visits to receive treatment if the woman or child 
was ill. Medical care was provided according to the standard of care at the study clinics and 
participants were provided with insecticide-treated bed nets. Clinical and laboratory adverse 
events identified at regular study visits and interim sick visits were documented and graded 
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according to toxicity tables from the National Institute of Allergy and Infectious Diseases 
Division of AIDS, 2004 version [24] with modifications to the neutropenia definitions 
implemented May 10th, 2006 [21].
The BAN study was approved by the Malawi National Health Science Research Committee 
and institutional review boards at the University of North Carolina at Chapel Hill and the 
U.S. Centers for Disease Control and Prevention (CDC). All women provided written, 
informed consent for specimen storage and laboratory studies.
Exposures
The 852 babies randomized to infant nevirapine received a daily dose of nevirapine that 
increased according to age, ranging from 10 mg daily in the first 2 weeks to 30 mg daily for 
weeks 19 through 28. The 849 mothers on the maternal ARV arm received Combivir (twice 
daily) and either nevirapine (200 mg) once-daily for 14 days and twice-daily through week 
28 (n=39), nelfinavir (1,250 mg) twice-daily through week 28 (n=146), or lopinavir (400 
mg) plus ritonavir (100 mg) twice-daily through week 28 (n=664). These changes to the 
maternal antiretroviral regimen were made for reasons of safety, availability, and potency 
[21]. Data on ARV adherence were collected at five follow-up visits, and mothers reported 
taking all their antiretroviral doses a mean of 89% of the time and giving all infant 
antiretroviral doses 94% of the time.
In accordance with the Malawi Ministry of Health and Population Guidelines and WHO 
guidelines on CPT [25, 26], CPT was initiated in the BAN study for eligible women and 
infants on June 13, 2006. Cotrimoxazole was provided to all mothers with CD4<500 cells/µl 
(480 mg twice daily) and to all infants (240 mg once daily) beginning at their first study visit 
after 6 weeks of age and taken through 36 weeks of age or until weaning occurred and HIV 
infection was ruled out.
Outcomes
The outcomes studied in this analysis included severe forms of the following hematologic 
toxicities: anemia, neutropenia and elevated ALT. For each outcome, severe toxicity was 
defined as exceeding the cutpoint for grade 3 or higher on the 2014 version of the Division 
of AIDS toxicity tables [27]. Severe neutropenia was defined as <600 cells/mm3. Severe 
anemia was defined as hemoglobin <8.5 g/dl for infants 56 days old or younger, and <9.5 
g/dl for infants older than 56 days. Severe elevated ALT was defined as ≥ 5.0 times the upper 
limit of normal range. Additionally, hemoglobin concentrations, neutrophil counts and ALT 
concentrations from full blood counts taken at scheduled study visits were used to assess 
hematologic changes longitudinally.
Statistical methods
To examine the effects of CPT from 6 to 36 weeks postpartum, the 28-week postnatal 
antiretroviral intervention, and their interaction, this analysis was limited to HEU infants 
with at least one full blood count at the 6, 8, 12, 18, 21, 24, 28, 32, 36, 42, and 48 week post-
partum study visits. This excluded 146 infants who were HIV-infected by 6 weeks of age, 17 
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HEU infants who died before 6 weeks of age and 200 infants lost to follow-up or with 
missing lab data. The final sample included 2006 infants.
Descriptive analyses included calculation of frequencies and medians for all exposures, 
outcomes and covariables. Categorical proportions were compared using chi-square tests and 
continuous variables were assessed using the Kruskal–Wallis test. To describe and illustrate 
the toxicity burdens suffered by the different groups, Cox proportional hazards models, one 
per outcome, were used to assess the hazards of severe hematologic toxicities by time-
dependent CPT status, ARV arm and their interaction, and did not include other covariates. 
The extended Kaplan-Meier method, as described by Snapinn, et al [28], was used to 
visualize the hazards assessed in the Cox models. Per the study protocol, infant follow-up 
was censored at death, maternal death, or loss to follow-up.
Linear mixed models were used to evaluate the effects of the time-dependent CPT exposure, 
ARV arm, and their interaction on continuous longitudinal measurements of hemoglobin, 
neutrophils, and ALT. To determine whether the medication effects varied with infant age, 
interactions between week of age and CPT exposure were evaluated and significant 
interaction terms were retained. Mixed models used an autoregressive covariance structure 
with a random effect for subject, and were adjusted for randomization to the maternal 
nutritional supplement arm, infant gender, birthweight, infant hematologic values measured 
at birth (neutrophil counts, hemoglobin and ALT concentrations), maternal factors measured 
at birth (CD4 count, body mass index and hemoglobin concentration) and rainy season 
(defined as November through March). In analyses considering time-varying CPT exposure, 
infants were considered exposed from the first visit at or later than 6 weeks postnatal until 
48 weeks, meaning CPT status will vary only for individuals actively in follow up when 
CPT was implemented. Study arm is modeled as an intent-to-treat variable. A sensitivity 
analysis was conducted, cutting off follow up for all participants at the discontinuation of the 
control group (March 27, 2008). Extended Kaplan Meier plots were created using R 3.3.2; 
all other analyses were performed using SAS 9.4.
Results
Among the 2,006 HEU infants, 553 were enrolled before and 1,453 after study 
implementation of the new CPT guidelines (Table 1). There was a small, but significant 
difference in median maternal BMI, with higher values in the group enrolled after CPT 
implementation; there were no other differences in maternal characteristics or infant sex and 
birthweight according to either CPT implementation or ARV treatment arm (Table 1). 
Prevalence of all three severe hematologic toxicities (anemia, neutropenia and elevated ALT) 
was low at baseline.
Over the course of follow up from 6 to 48 weeks of age, 10.5% of infants had at least one 
episode of severe anemia; by comparison, 3.5% and 0.8%, respectively had severe 
neutropenia and elevated ALT.
Initial episodes of severe anemia were less frequent for infants exposed to CPT than for 
those not exposed to CPT, especially after 24 weeks of age (Figure 1a), and CPT was 
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associated with a decreased hazard of severe anemia (HR: 0.65, 95% CI: 0.48 – 0.88) (Table 
2). Compared to the control arm, the infant nevirapine arm had a significantly lower hazard 
of severe anemia (HR: 0.68, 95% CI: 0.48 – 0.96) (Table 2). Most initial episodes of severe 
anemia occurred later in follow up (Figure 1c).
Cox proportional hazards models showed CPT exposure was associated with an increased 
hazard of severe neutropenia (HR: 1.97, 95% confidence interval (CI): 1.01 – 3.86) (Table 
2). Unlike severe anemia, most initial episodes of severe neutropenia during follow up 
occurred by 18 weeks of age (Figure 1b), regardless of CPT exposure. ARV treatment arm 
was not significantly associated with severe neutropenia (Table 2; figure 1d).
Neither CPT exposure nor ARV treatment arm assignment was associated with severe 
elevated ALT (Table 2). Models were also run with interaction terms between CPT exposure 
and weeks of age and between CPT exposure and ARV treatment arm for all of the 
outcomes studied, but none of the interactions tested showed statistical significance (data not 
shown).
Linear mixed models, used to analyze the longitudinal effects of CPT exposure on 
continuous hematologic outcomes, showed that CPT exposure was associated with increases 
in mean concentration of hemoglobin compared to infants not exposed to CPT, and that this 
association was modified by both ARV treatment and infant age. The significant interactions 
in this model mean the beta coefficients presented for this model in Table 3 represent 
changes in mean hemoglobin concentration compared to CPT-unexposed infants in the 
control arm at 12 weeks of age. They indicate that the observed association of CPT with 
mean hemoglobin was greater for infants in the control arm and for older infants. Using the 
mixed model coefficients, mean hemoglobin concentration was 0.18 g/dL (95% CI: 0.03, 
0.33) higher for those exposed to CPT in the control group at 12 weeks of age (Table 3). 
Mean hemoglobin concentration was higher in the maternal ARV and infant nevirapine arms 
compared to the control arm when not exposed to CPT (increases of 0.25 g/dL and 0.18 
g/dL, respectively at 12 weeks of age), but these effects of ARV treatment were diminished 
when exposed to CPT (decreases of 0.22 g/dL and 0.24 g/dL for maternal ARV and infant 
nevirapine arms, respectively) due to the significant interaction terms.
CPT exposure was associated with a 191.8 cells/mm3 decrease in mean neutrophil count 
(95% CI: −303.1, −80.6) in the control arm at 12 weeks of age, however this decrease was 
reduced by 7.8 cells/mm3 for each additional week of age due to a significant interaction 
term. There was no significant interaction between CPT and study arm in the model with 
neutrophil count as the dependent variable.
CPT exposure was not associated with ALT levels (increase of 0.53 IU/L, 95% CI: −0.68, 
1.74) (Table 3).
Results of the sensitivity analysis where follow up was cut off at the discontinuation of the 
control group yielded similar results to the main analysis (data not shown).
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Discussion
In this cohort of breastfed HEU infants followed until 48 weeks of life, severe anemia was 
relatively common, while severe neutropenia was rare. There was a significant decrease in 
severe anemia and a significant increase in severe neutropenia associated with CPT. 
Longitudinal mixed models showed corresponding increases in hemoglobin levels and 
decreases in neutrophil counts associated with CPT exposure. Associations between CPT 
and hemoglobin levels increased with age but were reduced by exposure to ARV (either 
maternal ARV or infant nevirapine). The reduction in neutrophil count associated with CPT 
exposure lessened with age.
A previous study on the effects of CPT on hematologic outcomes in HEU infants in 
Botswana showed that severe anemia and neutropenia were rare among HEU infants and 
there was no association between CPT and either outcome [29]. Our research confirms the 
low frequency of severe neutropenia in HEU infants, while the difference in frequency of 
severe anemia may be attributable to the different population studied. The BAN study took 
place in a region where malaria, a cause of anemia [30], is prevalent and all infants 
breastfed, while the previous study took place in a non-malarial region of Botswana and very 
few infants receiving CPT were breastfed. Nearly 50% of HEU infants in another study in 
Uganda and Zimbabwe (HPTN-046) who were taking CPT developed severe anemia and/or 
neutropenia [31]. However, that analysis focused on the effects of ARVs in the studied 
population, and did not present results for severe anemia and severe neutropenia separately; 
also, because all subjects were also exposed to CPT, the effects of each on the outcomes 
could not be determined.
While there is evidence from studies in adults that the combination of CPT and zidovudine-
containing ARV treatment may cause hematologic toxicities [32], our analysis shows that for 
HEU infants in areas of high malarial prevalence, it is possible that CPT may reduce the 
occurrence of severe anemia. In a separate analysis of data from the BAN trial, it was shown 
that CPT was associated with a reduction in sub-clinical malaria, although it had no effect on 
clinical malaria [33]. Thus, CPT may cause a reduction in malaria-related anemia separate 
from the drug’s direct effects on blood hemoglobin. Severe anemia in sub-Saharan Africa is 
associated with adverse clinical outcomes, including death [19, 34, 35], and the results of 
this analysis suggest that in populations with a high malaria prevalence, CPT has the 
potential to reduce the frequency of these outcomes among HIV-exposed infants.
This analysis did show an increase in severe neutropenia and a corresponding reduction in 
neutrophil counts associated with CPT. However, the effect on neutrophil count lessened 
with age, and the frequency of severe neutropenia was low even for those exposed to CPT. 
We did not find any association between CPT exposure and elevated ALT.
There was no overall difference in severe anemia or severe neutropenia according to ARV 
treatment arm, although those infants receiving daily nevirapine did have a lower estimated 
hazard of severe anemia compared with the control arm. Likewise, in longitudinal mixed 
models, both maternal ARV and infant nevirapine were associated with higher levels of 
hemoglobin in the absence of cotrimoxazole[36].
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This study instructed mothers to wean rapidly after 28 weeks, and self-reported adherence to 
the breastfeeding schedule was high. Median breastfeeding duration was 169 days, and did 
not vary by study arm. Median breastfeeding duration was 172 days for infants born before 
CPT implementation and 169 days for those born after (Kruskal-Wallis Test p-value < 
0.001). Current guidelines for HIV-infected women on ART recommend breastfeeding until 
12– 24 months [36]. HIV-uninfected mothers in Malawi generally continue breastfeeding 
until about 24 months, which means that the infants will continue to be exposed to ARVs 
and CPT. The reassuring findings of this study related to drug toxicities, combined with 
results from BAN and other studies showing increased morbidity and mortality in HIV-
exposed infants after early weaning suggest that the benefits of continued breastfeeding 
should outweigh concerns related to these exposures.
While a randomized controlled trial would be ideal to evaluate the hematologic effects of 
CPT in HEU infants in areas of high malaria prevalence, this is not possible or ethical 
following the release and implementation of CPT guidelines from the WHO and Malawi 
Ministry of Health. Thus, our analysis took advantage of the unplanned experiment caused 
by the BAN study’s implementation of CPT in June 2006 by treating CPT as a time-varying 
exposure. To account for secular trends in participants’ environments and health that may 
have confounded the association between CPT and the studied outcomes, longitudinal mixed 
models included factors indicative of maternal and infant health before entry into the 
analysis cohort at 6 weeks of age, along with variables to account for seasonal changes. 
Despite our ability to control for these factors, there may have been changes over time in 
participants’ health unrelated to CPT that we could not account for.
Changes in the study protocol over time may have affected results. An increase in the 
minimum CD4+ cell count for enrollment eligibility, from <200 to <250, 6 months after 
CPT implementation and changes to the maternal ARV regimen over time [21] may have led 
to the inclusion of healthier individuals later in the study, and changes in study population 
health unrelated to CPT. These changes should be at least partially addressed by the factors 
adjusted for in longitudinal mixed models, which included maternal CD4+ cell count. If 
changes to the maternal ARV regimen improved outcomes at around the same time as CPT 
implementation and inflated the observed positive associations between CPT and 
hemoglobin levels, this effect should show up in the maternal ARV arm. Instead, in linear 
mixed models, the positive association between CPT and hemoglobin levels was reduced in 
the maternal ARV arm compared to the control arm, and associations between CPT and 
other outcomes did not differ according to study arm (Table 3). Likewise, the similarity of 
the results of the sensitivity analysis to the main analysis indicate that the observed effect of 
CPT was not due to the shift, later in the study, of participants to the two intervention arms. 
Rates of analysis-specific exclusions were non-differential with respect to CPT 
implementation, so we do not have reason to expect bias to results. Most of the 146 HIV-
related exclusions were due to in-utero infection (n=119); post-natal pre-6 week visit 
infections (n=27) were more likely in the control group. If these excluded infants were more 
likely to suffer adverse study outcomes due to poor health, this could bias results related to 
the two ARV arms towards significant associations, but the number involved is small and 
any effect is unlikely to be large. Exclusions due to LTFU and infant deaths before the 6 
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week visit were non-differential by study arm. The results of this analysis may only apply to 
populations similar to the one studied.
The findings of this analysis further support the use of daily CPT among HEU infants, 
especially in areas of high malaria prevalence. There has been concern about the potential 
for the combined use of CPT and ARV treatment to cause hematologic toxicities. While our 
data suggest that CPT may increase the hazard of severe neutropenia, the overall prevalence 
of this outcome remained low. The reduction in severe anemia associated with CPT is an 
additional benefit for HEU infants at increased risk for adverse health outcomes and 
mortality.
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Figure 1. 
Extended Kaplan-Meier curves for the probabilities of severe anemia and severe 
neutropenia, as defined in the 2014 version of the Division of AIDS toxicity tables, 
according to time-varying cotrimoxazole (CPT) exposure status (panels a and b) and 
according to antiretroviral study arm (panels c and d) over follow up of HIV-exposed, 
uninfected infants in the Breastfeeding, Antiretrovirals and Nutrition (BAN) study in Malawi 
from 6 to 48 weeks of age (2004–2010).
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